In President Barack Obama’s final State of the Union address, he emphasized the “moonshot” need to cure cancer. At Weill Cornell Medicine and NewYork-Presbyterian Hospital, we are actively working towards that goal.
Through our use of gene sequencing and precision medicine, we are transforming the way cancer is characterized and treated. Using a multidisciplinary approach and the EXaCT-1 test, here at the Weill Cornell Genitourinary (GU) Oncology Program, we are able to sequence the genes of advanced stage cancer patients. We can then narrowly tailor personalized treatment regimens based on the genetic makeup of a patient’s tumor which indicates whether a cancer is likely to respond to a particular treatment therapy.
Irene Price came to Dr. David Nanus, Chief of the Division of Hematology and Medical Oncology, with metastatic bladder cancer, and had more than 20,000 genes sequenced with the EXaCT-1 test. Dr. Nanus and his colleagues determined that the reason she wasn’t responding to prior treatment rested in a specific genetic mutation within her tumor. As a result, the team was able to prescribe a personalized treatment regimen – one more often used in the treatment of breast cancer.
The results were life changing. It caused her cancer to completely disappear. According to Price, “I’ve had college graduations that I wouldn’t have had, weddings that I wouldn’t have had, and the birth of great grandchildren that I wouldn’t have had.”
Learn more about our personalized approach to cancer care in a two-part series on NY1:
Part 1: “Gene Sequencing Effort Helps Pinpoint Cancer Treatments”
Part 2: “Tailored Cancer Treatments Fit Doctors’ New Approach”
To make an appointment with one of our clinicians, please call 646-962-2072.
What's New in GU? 